



Euro-Med Laboratories Phil., Inc.

15 April 2024

TO THE BOARD OF DIRECTORS
EURO-MED LABORATORIES PHIL., INC.

This attestation letter is provided in connection with the audit of the financial statements of the Company **FOR THE YEAR ENDED DECEMBER 31, 2023.**

We confirm, to the best of our knowledge and belief, the following representations; such representations are as follows:


- There have been no irregularities involving management or employees who have a significant role in internal control or that could have a material effect on the financial statements;
- The Financial Statements, and other financial information included in the report (including, financial statements, footnotes to the financial statements, selected financial data, management's discussion and analysis of operations and financial condition and other financial information in the report), fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in the report.
- We have made available all books of account and supporting documentation and all minutes of meetings of shareholders and the board of directors for the year ended 31 December 2017;
- We confirm the completeness of the information provided regarding the identification of related parties;
- The financial statements are free of material misstatements, including omissions;
- The Company has complied with all aspects of contractual agreements that could have a material effect on the financial statements in the event of noncompliance. There has been no noncompliance with requirements of regulatory authorities that could have a material effect on the financial statements in the event of noncompliance;
- The following have been properly recorded and, when applicable, adequately disclosed in the financial statements:
 - The identity of, and balances and transactions with, related parties.
 - Losses arising from sale and purchase commitments.
 - Agreements and options to buy back assets previously sold.
 - Assets pledged as collateral.
- We have no plans or intentions that may materially alter the carrying value or classification of assets and liabilities reflected in the financial statements;
- We have no plans to abandon lines of product or other plans or intentions that will result in any excess or obsolete inventory, and no inventory is stated at an amount in excess of net realizable value;
- The Company has satisfactory title to all assets and there are no liens or encumbrances on the company's assets, except for those that are disclosed in Notes to the financial statements;
- We have recorded or disclosed, as appropriate, all liabilities, both actual and contingent, and have disclosed in Notes to the financial statements all guarantees that we have given to third parties;
- Other than described in Notes to the financial statements, there have been no events subsequent to period end, which require adjustment of or disclosure in the financial statements or Notes thereto;
- There are no formal or informal compensating balance arrangements with any of our cash and investment accounts. Except as disclosed in Notes to the financial statements, we have no other line of credit arrangements;
- We have properly recorded or disclosed in the financial statements the capital stock repurchase options and agreements, and capital stock reserved for options, warrants, conversions and other requirements;
- The management team acknowledges its responsibility for the adequacy system of financial, operational and compliance controls;



Euro-Med Laboratories Phil., Inc.

- All contingent liabilities have been disclosed;
- All unasserted claims or assessments have been disclosed;
- Fully complies with the requirements of the Bureau of Internal Revenue and the Securities and Exchange Commission, as applicable;
- Protecting system security and following corporate security policies;
- Adhering to Company policies and segregation of duties policies;
- A complete set of policies and procedures is prominently displayed on the Corporation's internal website at www.euromedlab.net;
- Periodic management oversight/audits are conducted to ensure compliance with company policies and procedures.
- Responsible for establishing and maintaining "disclosure controls and procedures" for the Corporation;
- Have designed disclosure controls and procedures to ensure that material information is made known to the auditors, particularly during the period in which the periodic report is being prepared;
- Have the risk management system fully discussed with the auditors, its adequacy and disclosure in the financial statements;
- Have evaluated the effectiveness of the company's disclosure controls and procedures;
- Have presented in the report their conclusions about the effectiveness of the disclosure controls and procedures based on the required evaluation.
- The other certifying officers have disclosed to the company's auditors and the Audit committee (or persons fulfilling the equivalent function):
 - all significant deficiencies in the design or operation of "internal controls" (a pre-existing term relating solely to financial reporting) which could adversely affect the company's ability to record, process, summarize and report financial data and have identified for the company's auditors any material weaknesses in internal controls; and
 - any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal controls;
- The other certifying officer have indicated in the report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.


MRS. GEORGIANA S. EVIDENTE
Chief Executive Officer


MR. JOSE A. EMITERIO
Senior Vice President/Compliance Officer